Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches

Seminars in Oncology

Volumn 36, Issue SUPPL. 1, 2009, Pages

  Wasik, Mariusz A ^a   Zhang, Qian ^a   Marzec, Michal ^a   Kasprzycka, Monika ^a   Wang, Hong Yi ^a   Liu, Xiaobin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 5 AZA 2' DEOXYCYTIDINE; ANAPLASTIC LYMPHOMA KINASE; AZACITIDINE; DNA METHYLTRANSFERASE 1; HERBIMYCIN A; HYBRID PROTEIN; IMATINIB; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NUCLEOPHOSMIN; NUCLEOPHOSMIN ANAPLASTIC LYMPHOMA KINASE FUSION PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; RAPAMYCIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UO 126; WORTMANNIN;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DRUG MECHANISM; GENE SILENCING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; LYMPHOMA, T-CELL; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 64849103123     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.02.007     Document Type: Article

References (78)

1. Morris S.W., Naeve C., Mathew P., James P.L., Kirstein M.N., Cui X., et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14 (1997) 2175-2188
2. Falini B., Bigerna B., Fizzotti M., Pulford K., Pileri S.A., Delsol G., et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 153 (1998) 875-886
3. Pulford K., Lamant L., Morris S.W., Butler L.H., Wood K.M., Stroud D., et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK protein in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89 (1997) 1394-1404
4. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
5. Mossé Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 16 (2008) 455 930-5
6. George R.E., Sanda T., Hanna M., Fröhling S., Luther II W., Zhang J., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 (2008) 975-978
7. Chiarle R., Voena C., Ambrogio C., Piva R., and Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8 (2008) 11-23
8. Borer R.A., Lehner C.F., Eppenberger H.M., and Nigg E.A. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56 (1989) 379-390
9. Chan W.Y., Liu Q.R., Borjigin J., Busch H., Rennert O.M., Tease L.A., et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 28 (1989) 1033-1039
10. Morris S.W., Kirstein M.N., Valentine M.B., Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263 (1994) 1281-1284
11. Shiota M., Fujimoto J., Semba T., Satoh H., Yamamoto T., and Mori S. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9 (1994) 1567-1574
12. Fujimoto J., Shiota M., Iwahara T., Seki N., Satoh H., Mori S., et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 93 (1996) 4181-4186
13. Bischof D., Pulford K., Mason D.Y., and Morris S.W. Role of the nucleophosmin (NPM) portion of the non Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 17 (1997) 2312-2325
14. Kuefer M.U., Look A.T., Pulford K., Behm F.G., Pattengale P.K., Mason D.Y., et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90 (1997) 2901-2910
15. Chiarle R., Gong J.Z., Guasparri I., Pesci A., Cai J., Liu J., et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 101 (2003) 1919-1927
16. Bai R.Y., Dieter P., Peschel C., Morris S.W., and Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18 (1998) 6951-6961
17. Bai R.Y., Ouyang T., Miething C., Morris S.W., Peschel C., and Duyster J. Nucleophosminanaplastic lymphoma kinase associated with anaplastic large cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96 (2000) 4319-4327
18. Slupianek A., Nieborowska-Skorska M., Hoser G., Morrione A., Majewski M., Xue L., et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61 (2001) 2194-2199
19. Slupianek A., and Skorski T. NPM/ALK down regulates p27Kip1 in a PI-3K-dependent manner. Exp Hematol 32 (2004) 1265-1271
20. Gu T.L., Tothova Z., Scheijen B., Griffin J.D., Gilliland D.G., and Sternberg D.W. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 103 (2004) 4622-4629
21. Zhang Q., Raghunath P.N., Xue L., Majewski M., Carpentieri D.F., Odum N., et al. Multilevel dysregulation of STAT3 activation in ALK+ T/null-cell lymphoma. J Immunol 168 (2002) 466-474
22. Zamo A., Chiarle R., Piva R., Howes J., Fan Y., Chilosi M., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (2002) 1038-1047
23. Darnell J.E. Validating Stat3 in cancer therapy. Nat Med 11 (2005) 595-596
24. Alvarez J.V., and Frank D.A. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Ther 3 (2004) 1045-1050
25. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
26. Groner B., Lucks P., and Borghouts C. The function of Stat3 in tumor cells and their microenvironment. Semin Cell Dev Biol 19 (2008) 341-350
27. Yue P., and Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 18 (2009) 45-56
28. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., and Raz R. Stat3 is required for ALK- mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11 (2005) 623-629
29. Nieborowska-Skorska M., Slupianek A., Xue L., Zhang Q., Raghunath P.N., Hoser G., et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 61 (2001) 6517-6523
30. Zhang Q., Wang H.Y., Liu X., and Wasik M.A. Stat5a is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nature Med 13 (2007) 1341-1348
31. Liu X., Robinson G.W., Wagner K.U., Garrett L., Wynshaw-Boris A., and Hennighausen L. STAT5A is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11 (1997) 179-186
32. Nakajima H., Liu X.W., Wynshaw-Boris A., Rosenthal L.A., Imada K., Finbloom D.S., et al. An indirect effect of STAT5A in IL-2-induced proliferation: a critical role for STAT5A in IL-2-mediated IL-2 receptor alpha chain induction. Immunity 7 (1997) 691-701
33. Davey H.W., Park S.H., Grattan D.R., McLachlan M.J., and Waxman D.J. STAT5B-deficient mice are growth hormone pulse-resistant. Role of STAT5B in sex-specific liver p450 expression. J Biol Chem 274 (1999) 35331-35336
34. Imada K., Bloom E.T., Nakajima H., Horvath-Arcidiacono J.A., Udy G.B., Davey H.W., et al. STAT5B is essential for natural killer cell-mediated proliferation and cytolytic activity. J Exp Med 188 (1998) 2067-2274
35. Marzec M., Kasprzycka M., Liu X., Raghunath P.N., Wlodarski P., and Wasik M.A. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26 (2007) 813-821
36. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6 (2006) 729-734
37. Petroulakis E., Mamane Y., Le Bacquer O., Shahbazian D., and Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94 (2006) 195-199
38. Corradettia M.N., and Guan K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?. Oncogene 25 (2006) 6347-6360
39. Marzec M., Kasprzycka M., Liu X., El-Salem M., Halasa K., Raghunath P.N., et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene 26 (2007) 5606-5614
40. Vega F., Medeiros L.J., Leventaki V., Atwell C., Cho-Vega J.H., Tian L., et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 66 (2006) 6589-6597
41. Kasprzycka M., Marzec M., Liu X., Zhang Q., and Wasik M.A. NPM/ALK oncoprotein induces T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 103 (2006) 9964-9969
42. Marzec M., Zhang Q., Goradia A., Raghunath P.N., Liu X., Paessler M., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 105 (2008) 20852-20857
43. Kasprzycka M., Zhang Q., Witkiewicz A., Marzec M., Potoczek M., Liu X., et al. Gamma c-signaling cytokines induce a regulatory T cell (Treg) phenotype in malignant CD4+ T lymphocytes. J Immunol 181 (2008) 2506-2512
44. Okazaki T., and Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Intern Immunol 19 (2007) 813-824
45. Keir M.E., Butte M.J., Freeman G.J., and Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008) 677-704
46. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114 (2004) 720-728
47. Ling X., and Arlinghaus R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65 (2005) 2532-2536
48. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 11 (2005) 623-629
49. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10 (2004) 48-54
50. Cheng F., Wang H.W., Cuenca A., Huang M., Ghansah T., Brayer J., et al. A critical role for Stat3 signaling in immune tolerance. Immunity 19 (2003) 425-436
51. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-692
52. van der Maarel S.M. Epigenetic mechanisms in health and disease. Ann Rheum Dis 67 Suppl 3 (2008) iii97-iii100
53. Wu C., Sun M., Liu L., and Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306 (2003) 1-12
54. Shultz L.D., Rajan T.V., and Greiner D.L. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotech 15 (1997) 302-307
55. Zhang Q., Raghunath P.N., Vonderheid E., Odum N., and Wasik M.A. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T cells results from methylation of the SHP-1 promoter. Am J Pathol 157 (2000) 1137-1146
56. Oka T., Ouchida M., Koyama M., Ogama Y., Takada S., Nakatani Y., et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62 (2002) 6390-6394
57. Khoury J.D., Rassidakis G.Z., Medeiros L.J., Amin H.M., and Lai R. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood 104 (2004) 1580-1581
58. Honorat J.F., Ragab A., and Lamant L. SHP1 tyrosine phosphatase negatively regulates NPM- ALK tyrosine kinase signaling. Blood 107 (2006) 4130-4138
59. Zhang Q., Wang H.Y., Marzec M., Raghunath P.N., Nagasawa T., and Wasik M.A. STAT3- and DNMT1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A 102 (2005) 6948-6953
60. Zhang Q., Wang H.Y., Woetmann A., Raghunath P.N., Odum N., and Wasik M.A. STAT3 induces transcription of the DNA methyltransferase 1 (DNMT1) gene in malignant T- lymphocytes. Blood 108 (2006) 1058-1064
61. Hehlmann R., Berger U., and Hochhaus A. Chronic myeloid leukemia: a model for oncology. Ann Hematol 84 (2005) 487-497
62. Turturro F., Arnold M.D., Frist A.Y., and Pulford K. Model of inhibition of the NPM-ALK kinase activity by Herbimycin A. Clin Cancer Res 8 (2002) 240-245
63. Ergin M., Denning M.F., Izban K.F., Amin H.M., Martinez R.L., Saeed S., et al. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol 29 (2001) 1082-1090
64. Marzec M., Kasprzycka M., Ptasznik A., Wlodarski P., Zhang Q., Odum N., et al. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Lab Invest 85 (2005) 1544-1554
65. Wan W., Albom M.S., Lu L., Quail M.R., Becknell N.C., Weinberg L.R., et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107 (2006) 1617-1623
66. Galkin A.V., Melnick J.S., Kim S., Hood T.L., Li N., Li L., et al. Identification of NVP-TAE684: a potent, selective and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104 (2007) 270-275
67. Li R., and Morris S.W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28 (2008) 372-412
68. Claus R., and Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 22 (2003) 6489-6496
69. Momparler R.L. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin Hematol 42 Suppl (2005) S9-S16
70. Momparler R.L. Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 32 (2005) 443-451
71. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
72. Xi S., Gooding W.E., and Grandis J.R. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 24 (2004) 970-979
73. Ling X., and Arlinghaus R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65 (2005) 2532-2536
74. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3 (2004) 261-269
75. Pulford K., Falini B., Banham A.H., Codrington D., Roberton H., Hatton C., et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood 96 (2000) 1605-1607
76. Passoni L., Scardino A., Bertazzoli C., Gallo B., Coluccia A.M., Lemonnier F.A., et al. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99 (2002) 2100-2106
77. Chiarle R., Martinengo C., Mastini C., Ambrogio C., D'Escamard V., Forni G., et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 14 (2008) 676-680
78. Webster W.S., Thompson R.H., Harris K.J., Frigola X., Kuntz S., Inman B.A., et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J Immunol 179 (2007) 2860-2869